Jazz Pharmaceuticals plc — Director's Dealing 2018

Aug 14, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2018-08-09

Reporting Person: Schnee Elmar (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-08-09	Ordinary Shares	A	1495	$0.0	Acquired	6836	Direct
2018-08-10	Ordinary Shares	S	742	$176.6104	Disposed	6094	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-08-09	Non-Qualified Stock Option (right to buy)	$177.73	A	3735	Acquired	2028-08-08	Ordinary Shares (3735)	Direct

Footnotes

F1: These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 2, 2019.

F2: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.61 to $176.872, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

F4: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2018.